IXICO (IXI), a medical imaging advanced analytics company specialising in neuroscience, has said that it has signed a deal with a new client to provide its imaging services in a clinical trial of a novel therapeutic to treat Progressive Supranuclear Palsy, a rare neurodegenerative disorder.

The contract is estimated to be worth approximately US$1.7 million (around £1.3 million) and spans a duration of four years. According to the World Health Organisation, rare diseases are defined as conditions affecting fewer than 65 individuals per 100,000 population.

Giulio Cerroni, CEO of IXICO, commented: "Rare diseases are a global health priority with about 95% of all rare diseases not yet having treatments. This new contract exemplifies the traction we are building beyond our strong market position in HD into other rare neuro disorders to expand our market opportunities and acquire new clients in the dynamic field of rare neurological diseases."
 

View from Vox 

Alongside dedicating research to Progressive Supranuclear Palsy, IXICO aims to provide insights that advance investigational therapies for neurological diseases such as Huntington's disease, Parkinson's disease, and Alzheimer's disease. This is done by converting complex data into clinically meaningful insights, which can help to meet significant unmet medical needs for neurological disorders. 

Notably, the company focuses on leveraging artificial intelligence, which has the potential to increase success-rates of clinical trials, reduce the cost of running them as well as reducing the burden on trial participants.

IXICO has seen a string of contract wins in 2023, including a contract with an existing client for a Huntington's disease Ph2b trial worth £2 million, following a contract win for a Phase 1/2 rare neurodegenerative disease gene therapy study valued at £0.7 million just a few months earlier. As of 31 March 2023, IXICO had won contracts totalling £11.6m over the previous twelve months, and with the aforementioned contracts added to the pipeline IXICO looks set to continue along this strong trajectory. 

Follow IXICO for more News and Updates:  IXI